rxstat › Classes › Other Antineoplastic Agents

Other Antineoplastic Agents: shortage status in Canada

5 of the 17 other antineoplastic agents rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Widespread shortageCarboplatin2 of 3 reported products affected Partial shortageAmsacrine1 of 1 reported products affected Partial shortageArsenic Trioxide1 of 3 reported products affected Partial shortageEribulin1 of 1 reported products affected · est. return Dec 31, 2026 Partial shortageErlotinib3 of 14 reported products affected · est. return Jun 30, 2027 Shortage anticipatedOxaliplatin0 of 6 reported products affected Shortage anticipatedVemurafenib0 of 1 reported products affected No current shortageAminolevulinic Acid No current shortageAnagrelide DiscontinuedAsparaginase0 of 2 reported products affected DiscontinuedEstramustine0 of 1 reported products affected No current shortageHydroxyurea No current shortageIpilimumab No current shortageMethyl Aminolevulinate DiscontinuedOfatumumab0 of 2 reported products affected DiscontinuedOlaparib0 of 1 reported products affected DiscontinuedPembrolizumab0 of 1 reported products affected

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.